Metastatic

Type: Keyphrase
Name: Metastatic
First reported 24 mins ago - Updated 24 mins ago - 1 reports

New drug shows promise in early studies for metastatic breast cancer

Share this article:The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer, particularly for those with hormone receptor (HR)-positive disease. ... [Published Chemotherapy Advisor - 24 mins ago]
First reported 21 hours ago - Updated 1 hour ago - 6 reports

The Lancet Publishes Phase III Trial Of Nevaxar For Thyroid Cancer

By Estel Grace MasangkayBayer HealthCare and Onyx Pharmaceuticals, an Amgen subsidiary, announced that The Lancet published online results from its Phase III DECISION trial. Trial results showed that Nevaxar (sorafenib) tablets significantly extended ... [Published Bioresearch Online - 1 hour ago]
First reported Apr 23 2014 - Updated 7 hours ago - 1 reports

Cancer Spread’s ‘Family Tree’

The process of metastasis— a tumor’s ability to spread to other parts of the body— is still poorly understood. It has not been easy to determine whether metastasis began early or late in the development of the primary tumor, or whether individual metastatic ... [Published Bioscience Technology Online - Apr 23 2014]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Hemolytic Anemia and Metastatic Carcinoma: Case Report and Literature Review [CASE STUDIES]

AbstractHemolytic anemia can complicate the development of a variety of solid tumors and hematologic malignancies. Although patientsmay have an established diagnosis with documented metastases, microangiopathic hemolytic anemia (MAHA) can be a presen ... [Published Lab Medicine - 23 hours ago]
First reported Apr 23 2014 - Updated 23 hours ago - 2 reports

Heat On Roche To Cut Kadcyla Price After National Institute for Clinical Excellence (NICE) Says "No"

Breast cancer care campaigners have slammed draft guidelines from the National Institute for Health and Care Excellence turning down NHS funding for Roche's Kadcyla (trastuzumab emtansine) because it costs "tens of thousands of pounds more than other ... [Published BioSpace - Apr 23 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Anti-HER2 Combo Active in Metastatic Breast Cancer

Dual HER2-targeted treatment with trastuzumab emtansine (T-DM1) and pertuzumab resulted in positive antitumor activity in patients with HER2-positive, locally advanced or metastatic breast cancer, with an overall response rate of 41%.According to Kathy ... [Published Cancernetwork.com - Apr 23 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 4 reports

FDA Fast Tracks OncoGenex Drug for Prostate Cancer

OncoGenex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic ... [Published Drug Discovery and Development - Apr 23 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 2 reports

New Canada-Israel research partnership to identify molecular drivers of metastatic pancreatic cancer

Canada NewsWireTORONTO, April 23, 2014TORONTOPancreatic cancer remains the most deadly common solid tumour in developed countries. Approximately 80 per cent of patients present with advanced disease, are not eligible for surgery and have extremely poor ... [Published Digital Journal - Apr 23 2014]
First reported Apr 22 2014 - Updated Apr 23 2014 - 2 reports

EORTC and SIOG update expert opinion on management of elderly patients with NSCLC

( European Organisation for Research and Treatment of Cancer ) In an article appearing in the Annals of Oncology, the EORTC Cancer in the Elderly Task Force and Lung Cancer Group along with the International Society for Geriatric Oncology have updated ... [Published Infrosoft - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 5 reports

Research and Markets Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies ...

"Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic ... ... [Published Big News Network - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 8 reports

Lilly's Cyramza first FDA-approved drug for advanced gastric cancer after prior chemo

The US Food and Drug Administration has approved pharma major Eli Lilly’s (NYSE: LLY) Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease ... [Published Pharma Letter - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

Metastatic Hormone Refractory Castration Resistant AndrogenIndependent Prostate Cancer Global Clinical Trials Review H1 2014

Recently added to the BioPortfolio report store, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 is a new report fromGlobalData published on 2014-04-14.This 177-page report ... [Published BioPortfolio - Apr 22 2014]

Quotes

That is a shame, according to the essayists. They speculate that "if just half of the 32,000 patients who die of prostate cancer annually in the United States were treated with ketoconazole instead of abiraterone" payers would save more than $1 billion per year
Allan says in metastasis, there's a theory called the seed and soil hypothesis. "Analogous to a dandelion, when it goes to seed, the seeds blow all over the place. But they don't necessarily grow everywhere they land; they grow only in congenial soil that has the right nutrients that support growth of seeds in a foreign environment. In the situation of metastasis, the tumor cells (" seeds') have some inherent factors that determine their aggressiveness and ability to metastasize, while the different organs ('soil') are believed to...
"Next, depending on the clinical indications, recommendations for surgery or alternative therapies are provided. In the case of surgery, an understanding of the true pathology will not be obtained until several days after surgical resection. Needle biopsy is occasionally performed in the pre-treatment setting in those cases where risks of competing malignancies may exist, when a benign process is suspected, or prior to ablation procedures."

More Content

All (2143) | News (1909) | Reports (0) | Blogs (197) | Audio/Video (0) | Fact Sheets (2) | Press Releases (21)
sort by: Date | Relevance
New drug shows promise in early studies for met... [Published Chemotherapy Advisor - 24 mins ago]
Celgene Corporation's CEO Discusses Q1 2014 Res... [Published Yahoo! Finance - 29 mins ago]
Five Comparative Cancer Drug Trials Unlikely to... [Published Diabetes Care - 1 hour ago]
Experiencing déjà vu [Published FOXNews.com - 1 hour ago]
The Lancet Publishes Phase III Trial Of Nevaxar... [Published Bioresearch Online - 1 hour ago]
New study helps to explain why breast cancer of... [Published Bio-Medicine - 3 hours ago]
FDA Approves Ramucirumab (Cyramza) for Gastric ... [Published Cancernetwork.com - 3 hours ago]
Cancer Genetics : Patent Application Titled "Pa... [Published 4 Traders - 3 hours ago]
Patent Application Titled "Cancer Imaging and T... [Published 4 Traders - 3 hours ago]
New study helps to explain why breast cancer of... [Published EurekAlert! - 4 hours ago]
Early promise against melanoma from new antibod... [Published Chemotherapy Advisor - 5 hours ago]
Non-Invasive Blood Test to Detect Prostate Canc... [Published Chemotherapy Advisor - 5 hours ago]
Updated Results Announced for ThermoDox Use for... [Published Chemotherapy Advisor - 5 hours ago]
AbbVie initiates Phase III non-small cell lung ... [Published Individual.com - 6 hours ago]
Finding Anticancer Drugs in Unlikely Places [Published General Medicine eJournal - 6 hours ago]
MacroGenics announces encouraging preclinical d... [Published Individual.com - 6 hours ago]
BIND Therapeutics announces encouraging data fr... [Published Individual.com - 6 hours ago]
J&J snags FDA OK for rare blood disorder drug s... [Published FierceBiotech - 7 hours ago]
Forum Post: RE: Why is everything so hard to do... [Published Macmillan Cancer Support - 8 hours ago]
US FDA permits Helix to initiate clinical trial... [Published PharmaBiz - 8 hours ago]
Eli Lilly's Cyramza becomes first FDA-approved ... [Published Pharmaceutical Technology - 8 hours ago]
New drug to treat stomach cancer approved by FD... [Published Cleveland.com - 10 hours ago]
Lung cancer [Published The Gulf Today - 11 hours ago]
Morcellation Lawsuit Examines Procedure; FDA Ca... [Published EMAILWIRE.com - 13 hours ago]
Positive Results from Phase III DECISION Study ... [Published PipelineReview - 13 hours ago]
AstraZeneca PLC first quarter results 2014 [Published AstraZeneca - 14 hours ago]
AstraZeneca Q1 operating profit hit by shrinking [Published Telegraph - 14 hours ago]
Thyroid cancer [Published Lancet - 15 hours ago]
Myth? Massages spread cancer around the body (1) [Published Australian Doctor - 16 hours ago]
Therapeutic targeting of BET bromodomain protei... [Published BioPortfolio - 17 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Articles] Sorafenib in radioactive iodine-refr... [Published The Lancet online - 21 hours ago]
Sorafenib significantly improved progression-free survival compared with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid cancer. Adverse events were consistent with the known safety profile of sorafenib. These ...
Phase 3 DECISION Trial of NEXAVAR (sorafenib) i... [Published PR Newswire: Health - 21 hours ago]
WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published ...
Paying It Forward [Published New. Clear. Vision. - Apr 23 2014]
Thoughts on ‘Authentic Carbon Trading’ by Missy Beattie Recently, I read an article about the aging population, specifically, those who have Alzheimer’s and other forms of dementia, and the burden placed on families, society, and health care.  ...
OncoGenex Announces Fast Track Designation Gran... [Published PR Newswire: Health - Apr 23 2014]
BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen ...
Research and Markets: Global Metastatic Renal C... [Published Business Wire Health News - Apr 22 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t4tr2p/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Lion Biotechnologies' Lead Program With Nationa... [Published GlobeNewswire: Advertising News - Apr 07 2014]
Immunicum submits the final report for its phas... [Published GlobeNewswire: Acquisitions News - Mar 31 2014]
Immunicum’s abstract with data from a kidney ca... [Published GlobeNewswire: Acquisitions News - Mar 27 2014]
Cometriq® approved in Europe for the treatment ... [Published GlobeNewswire: Acquisitions News - Mar 25 2014]
Delcath Systems Analyst Report by BrokerBank Se... [Published Financial Services - Mar 24 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.